COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies, such as booster doses, appear warranted in this population.
Kidney Cancer
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Bacterial Supplement May Improve CPI Outcomes in Metastatic Kidney Cancer
In a phase 1 trial, investigators tested whether an oral supplement containing a strain of Clostridium butyricum increases the abundance of certain gut bacteria known to be associated with a better response to immune checkpoint inhibitors.
ICI-Based Urologic Cancer Therapies Tied to High Adverse Event Rates
Treatment-related adverse events of any grade develop in the majority of patients who receive urologic cancer therapies based on immune checkpoint inhibitors, according to a study.
Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
Progression-free, overall survival significantly longer with combo versus sunitinib for advanced renal cell carcinoma
Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
Progression-free survival longer and response rate greater for cabozantinib versus sunitinib in phase 2 trial in adults with PRCC
Biomarkers Identify Immune Checkpoint Inhibitor-Related Acute Kidney Injury
Prompt diagnosis of AKI and the ability to rule out immune checkpoint inhibitors as the cause may allow patients to continue with cancer immunotherapy.
Opdivo Plus Cabometyx Approved for Advanced Kidney Cancer
The approval was based on data from the randomized, open-label phase 3 CheckMate-9ER.
